PVP Labs

Taphalgin API was registered with the Ministry of Health of Russia.

admin 12/02/2019 No comments

Search for:

2022 Phase 3 Clinical trials of Taphalgin for patients with chronic pain have been successfully completed.
Phase 3 Clinical trials of Taphalgin have commence for patients suffering with postoperative pain.
PVP Labs Group has been established in the UAE, to develop the market for PVP products in the Middle East, India, and Africa.
PVP Labs has established Taph Corporation in the United States, with the primary goal of further developing the market for Taphalagin in America. Taphalgin is PVP’s non-narcotic pain management drug; patented in the US and Canada.
PVP Labs discovers – a life-saving solution that can be used during the early phase of viral infections, to assist humanity in its’ struggle against the viral spread